文献速递膀胱癌与上尿路尿路上皮癌

尿细胞学可用于评估BCG治疗后膀胱红斑性病变

Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guérin (BCG) treatment.
PubMed 文献 · BJU Int · 2018-08-12

该回顾性研究纳入159例接受BCG灌注的非肌层浸润性膀胱癌患者,分析367次活检。乳头状或扁平肿瘤中76%活检为恶性,细胞学诊断价值有限;红斑性病变占活检目标的57%,仅10%为恶性,尿细胞学阴性时或可避免活检。

要点

  • BCG治疗后乳头状或扁平肿瘤应活检或切除,细胞学灵敏度仅33%。
  • 红斑性病变多数为炎症,仅10%为恶性,细胞学阴性预测值达94%。
  • 尿细胞学阴性时或可避免对红斑性病变活检。

核心结论

  • BCG治疗后膀胱病变不应忽视,红斑性病变可能隐藏恶性肿瘤;乳头状或扁平肿瘤应活检,红斑性病变细胞学阴性或可避免活检。

研究设计与样本

  • 回顾性研究纳入2009-2015年两中心206例连续NMIBC患者中159例,中位随访35个月,分析367次活检。

主要发现

  • 乳头状或扁平肿瘤活检76%为恶性,细胞学灵敏度33%、特异度84%。
  • 红斑性病变占活检目标57%,多数为慢性非特异性或肉芽肿性炎症,10%病理为恶性。
  • 红斑性病变细胞学灵敏度59%、特异度76%、PPV 23%、NPV 94%。

关键数值与推荐

  • 乳头状或扁平肿瘤:活检恶性率76%,细胞学灵敏度33%、特异度84%。
  • 红斑性病变:恶性率10%,细胞学灵敏度59%、特异度76%、PPV 23%、NPV 94%。

临床怎么用

  • BCG随访中乳头状或扁平肿瘤应活检或切除;红斑性病变若尿细胞学阴性可考虑避免活检。

局限性

  • 回顾性设计,样本来自两家医院,结论需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the need to biopsy erythematous lesions of the bladder after bacille Calmette-Guérin (BCG) treatment as well as the diagnostic value of voided urine cytology in the detection of recurrence. MATERIALS AND METHODS: Data on 206 consecutive patients with non-muscle-invasive bladder cancer treated with one or more BCG instillations in the period 2009-2015 at Satakunta Central Hospital and Turku University Hospital were reviewed. Biopsy histology was pooled according to lesion cystoscopy appearance regarding growth pattern and presence of erythema. Voided urine cytology grading before resection was reviewed. We correlated the cystoscopy findings with histology and calculated the sensitivity, specificity, and positive (PPV) and negative predictive value (NPV) for voided urine cytology. RESULTS: In total, 159 patients with a median follow-up of 35 months were included in the study. Altogether, 367 biopsies were analysed. In the case of papillary or flat tumours, 76% of biopsies showed malignant histology and the diagnostic value of cytology was very limited (sensitivity 33%, specificity 84%). Erythematous lesions constituted 57% of all biopsy targets, with the majority being either chronic non-specific inflammation or granulomatous inflammation; 10% of erythematous lesions were malignant at pathological examination. In contrast to papillary and flat tumours, cytology proved to be more accurate in the case of erythematous lesions with a sensitivity, specificity, PPV and NPV of 59%, 76%, 23% and 94%, respectively. CONCLUSION: Bladder lesions after BCG instillations pose a challenge during follow-up and the appropriate management strategy is not clear. Lesions should not be overlooked as being BCG-induced irritation because they may harbour significant malignancies. The presence of papillary or flat tumour always warrants a biopsy or resection. In the case of erythematous lesions, our results suggest that biopsy may be avoided if voided urine cytology is negative.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Nurminen P, Ettala O, Seppänen M, et al. Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guérin (BCG) treatment. BJU Int. 2018. PMID: 29959824. doi:10.1111/bju.14470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。